Vagus Nerve Stimulation Modulates T-Cell Activity to Inhibit TNF

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for modulating the inflammatory reflex to control cytokine production during inflammatory responses are incomplete, as the role of T cells in the cholinergic anti-inflammatory pathway was unknown, and existing treatments fail to effectively inhibit TNF production in certain conditions.

Innovation Solution

Stimulating the inflammatory reflex, specifically through vagus nerve stimulation, in combination with administering T-cell modifying agents, such as nicotine or glucocorticoids, to modulate T-cell activity and inhibit TNF production, which is essential for controlling cytokine release.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If vagus nerve stimulation is used to inhibit cytokine production, then anti-inflammatory effect is improved, but treatment completeness deteriorates because T-cell role was unknown and TNF production not effectively inhibited

Engineering Contradiction:

Improveanti-inflammatory effectVSAvoidtreatment completeness

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent identifies T cells as intermediary components in the cholinergic anti-inflammatory pathway. Vagus nerve stimulation releases acetylcholine that acts on alpha7 nAChR expressed on T cells, which then mediate the suppression of cytokine production by macrophages. This intermediary role of T cells completes the previously unknown mechanism and enables effective TNF production inhibition.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If T-cell modifying agents are administered alone, then T-cell activity is modulated, but inflammatory response control is insufficient without vagus nerve stimulation

Engineering Contradiction:

ImproveT-cell activity modulationVSAvoidinflammatory response control

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent combines two therapeutic approaches: vagus nerve stimulation and T-cell modifying agent administration. The vagus nerve stimulation provides neural regulation through acetylcholine release, while T-cell modifying agents directly enhance T-cell function. Together, they synergistically improve inflammatory response control by targeting multiple points in the cholinergic anti-inflammatory pathway.

Inventive Principle:

Principle #5Merging (Combining)

3Adaptability or versatility

If alpha7 nAChR signals are blocked, then cholinergic pathway function is eliminated, but sensitivity to endotoxins increases excessively

Engineering Contradiction:

Improvecholinergic pathway functionVSAvoidendotoxin sensitivity

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary anti-action by administering T-cell modifying agents before or during vagus nerve stimulation to pre-enhance T-cell function. This ensures that when acetylcholine is released from the vagus nerve, the T cells are already in an optimal state to mediate cytokine suppression, preventing excessive endotoxin sensitivity that would occur if the cholinergic pathway were blocked.

Inventive Principle:

Principle #9Preliminary anti-action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively attenuates TNF production by targeting T cells, demonstrating a critical role in the cholinergic anti-inflammatory pathway, and provides a method for treating T-cell mediated diseases like rheumatoid arthritis and multiple sclerosis.

Implementation Method 1

neuromodulation of T-cell activity

Methodology Applied

Scientific EffectNeuromodulation:

Implementation Method 2

The cholinergic anti-inflammatory pathway is an anti-inflammatory neural mechanism for suppressing cytokine release by the immune system. It functions by signals carried via the vagus nerve that suppress cytokine release through a molecular mechanism that requires the alpha7 nicotinic acetylcholine receptor subunit (alpha7 nAChR).

Methodology Applied

Scientific EffectCholinergic signaling:

Implementation Method 3

Administration of nicotine, an alpha7 agonist, significantly attenuates TNF production by the subpopulation TNF-producing splenic macrophages.

Methodology Applied

Scientific EffectReceptor binding:

Data Source

PatentUS9211409B2Methods and systems for reducing inflammation by neuromodulation of T-cell activity

Publication Date: 2015.12.15 THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH

AI summary

Described herein are devices, systems and method of treating inflammation, including methods of treating a T-cell mediated disease. In particular, described herein are methods of treating inflammation including the steps of stimulating a subject's inflammatory reflex to inhibit the immune response and administering a T-cell modifying agent to modify the activity of splenic T-cells. Also described herein are systems for treating inflammation including an inflammatory reflex stimulation module and a T-cell response modifying module. The T-cell response modifying module typically modifies the response of splenic T-cells to enhance or otherwise regulate the effect of stimulation of the inflammatory reflex.